Business Description
NeoPharm Co Ltd
ISIN : KR7092730001
Compare
Compare
Traded in other countries / regions
092730.Korea IPO Date
2007-01-30Description
NeoPharm Co Ltd is a South Korean company operating in the household and personal products. The products of the company include skin care brand, skin barrier special dermo cosmetic brand, hospital functional products, and life moisturizing body professional brand.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 105.13 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | 1186.85 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 9.11 | |||||
| Beneish M-Score | -2.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.3 | |||||
| 3-Year EBITDA Growth Rate | 8.6 | |||||
| 3-Year EPS without NRI Growth Rate | 8.9 | |||||
| 3-Year FCF Growth Rate | -46.8 | |||||
| 3-Year Book Growth Rate | 10.8 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.74 | |||||
| 9-Day RSI | 48.1 | |||||
| 14-Day RSI | 45.4 | |||||
| 6-1 Month Momentum % | -5.54 | |||||
| 12-1 Month Momentum % | 34.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.94 | |||||
| Quick Ratio | 7.34 | |||||
| Cash Ratio | 6.61 | |||||
| Days Inventory | 110.18 | |||||
| Days Sales Outstanding | 29.51 | |||||
| Days Payable | 58.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.25 | |||||
| Dividend Payout Ratio | 0.25 | |||||
| 3-Year Dividend Growth Rate | 4.9 | |||||
| Forward Dividend Yield % | 3.25 | |||||
| 5-Year Yield-on-Cost % | 3.54 | |||||
| Shareholder Yield % | 3.12 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.34 | |||||
| Operating Margin % | 26.06 | |||||
| Net Margin % | 23.91 | |||||
| FCF Margin % | 2.51 | |||||
| ROE % | 15.5 | |||||
| ROA % | 14.05 | |||||
| ROIC % | 58.84 | |||||
| ROC (Joel Greenblatt) % | 169.57 | |||||
| ROCE % | 19.61 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 7.96 | |||||
| PE Ratio without NRI | 7.87 | |||||
| Shiller PE Ratio | 11.84 | |||||
| Price-to-Owner-Earnings | 7.67 | |||||
| PEG Ratio | 1.71 | |||||
| PS Ratio | 1.9 | |||||
| PB Ratio | 1.15 | |||||
| Price-to-Tangible-Book | 1.17 | |||||
| Price-to-Free-Cash-Flow | 75.77 | |||||
| Price-to-Operating-Cash-Flow | 7.94 | |||||
| EV-to-EBIT | 2.5 | |||||
| EV-to-EBITDA | 2.38 | |||||
| EV-to-Revenue | 0.76 | |||||
| EV-to-FCF | 29.93 | |||||
| Price-to-Projected-FCF | 0.66 | |||||
| Price-to-DCF (Earnings Based) | 0.23 | |||||
| Price-to-DCF (FCF Based) | 4.31 | |||||
| Price-to-Median-PS-Value | 0.46 | |||||
| Price-to-Graham-Number | 0.64 | |||||
| Price-to-Net-Current-Asset-Value | 1.58 | |||||
| Price-to-Net-Cash | 1.95 | |||||
| Earnings Yield (Greenblatt) % | 39.9 | |||||
| FCF Yield % | 1.31 | |||||
| Forward Rate of Return (Yacktman) % | 11.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NeoPharm Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 97,104.89 | ||
| EPS (TTM) (â‚©) | 2969 | ||
| Beta | 0.56 | ||
| Volatility % | 42.27 | ||
| 14-Day RSI | 45.4 | ||
| 14-Day ATR (â‚©) | 842.724795 | ||
| 20-Day SMA (â‚©) | 23857.5 | ||
| 12-1 Month Momentum % | 34.97 | ||
| 52-Week Range (â‚©) | 17460 - 29450 | ||
| Shares Outstanding (Mil) | 7.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NeoPharm Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NeoPharm Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
NeoPharm Co Ltd Frequently Asked Questions
What is NeoPharm Co Ltd(XKRX:092730)'s stock price today?
The current price of XKRX:092730 is â‚©23600.00. The 52 week high of XKRX:092730 is â‚©29450.00 and 52 week low is â‚©17460.00.
When is next earnings date of NeoPharm Co Ltd(XKRX:092730)?
The next earnings date of NeoPharm Co Ltd(XKRX:092730) is .
Does NeoPharm Co Ltd(XKRX:092730) pay dividends? If so, how much?
The Dividend Yield %  of NeoPharm Co Ltd(XKRX:092730) is 3.25% (As of Today), Highest Dividend Payout Ratio of NeoPharm Co Ltd(XKRX:092730) was 0.53. The lowest was 0.25. And the median was 0.31. The  Forward Dividend Yield % of NeoPharm Co Ltd(XKRX:092730) is 3.25%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers